摘要
目的采用简明健康测量量表MOS SF-36对维持性血液透析患者在静脉用右旋糖酐氢氧化铁注射液治疗前后生存质量进行评价，以探讨静脉补铁剂对患者贫血和生存质量的干预作用。方法选择慢性肾衰竭行维持性血液透析患者43例，分为静脉用铁剂治疗组（A组）和口服铁剂治疗组（B组），所有患者在纳入研究后采用MOS SF-36量表进行基础评分，在接受静脉补铁治疗10次后再次填写调查表进行评分。结果静脉补铁后患者贫血指标明显改善，与口服补铁患者比较血红蛋白（Hb）升高有统计学差异（P〈0．01），而且静脉补铁患者在生存质量的所有纬度上均较治疗前明显改善，同时与口服补铁患者相比较在生理功能（PF）、总体健康（GH）、活力（VT）、社会功能（SF）、情感职能（RE）、精神健康（MH）等方面具有统计学差异（P〈0．05）。结论静脉补铁剂可有效改善血液液透析患者的贫血状态，提高其患者的生存质量。
Objective To investigate the effect of intravenous ferric hydroxide dextran and oral ferrous succinate therapy on sustained hemodialysis patients with severe anemia. Method Fourty three patients were divided into 2 groups： intravenous and oral iron group. SF-36 was used to evaluate the health related quality of life in hemodialysis patients while hemoglobin, heamatocrit, serum ferritin and transferrin saturation levels were measured before and after treatment. Results Hemoglobin, heamatocrit, serum ferritin and transferrin saturation levels were significantly increased and those parameters are higher in the intravenous irons group than oral iron group （P〈0. 01）. The values of physical functioning,general health, vitality, social functioning, role-emotional and mental health were significantly higher in the intravenous iron group as compared to the oral iron group. Conclusions Intravenous iron supplement can quickly and effectively improve anemia us and life quality in hemodialysis patients.
出处
《临床肾脏病杂志》
2008年第1期9-11,共3页
Journal Of Clinical Nephrology
